This program is intended for community-based medical hematologists/oncologists, advanced practice providers, nurses, pharmacists, physician assistants/physician associates, and other healthcare professionals involved in the treatment of patients with myelofibrosis.
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in the use of evidence-based and guideline-directed best practices in the care of patients with MF.
Upon completion of this activity, participants should be able to:
Plan first-line therapy for patients with MF based on available data and expert recommendations, taking risk stratification, platelet counts, and symptom burden into account
Recognize the symptoms and patterns of suboptimal first line treatment response in patients with MF, including treatment intolerance and treatment resistance
Plan evidence-based therapeutic strategies for patients with MF and a suboptimal response to first-line JAK inhibitor therapy
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Raajit K. Rampal, MD, PhD
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Raajit Rampal, MD, PhD: consultant/advisor: AbbVie, Blueprint, Celgene/Bristol Myers Squibb, CTI, Galecto, GlaxoSmithKline/Sierra, Incyte, Kartos, Karyopharm, MorphoSys/Constellation, PharmaEssentia, Servier, Sumitomo Dainippon, Zentalis; researcher: Constellation, Incyte, Ryvu, Stemline, Zentalis.
Srdan Verstovsek, MD, PhD
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Srdan Verstovsek, MD, PhD: researcher: Bristol Myers Squibb, Constellation, CTI, Gilead, Incyte, Kartos, Novartis, NS Pharma, PharmaEssentia, Protagonist, Roche, Sierra, Telios.
Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Brady Stein, MD, MHS: consultant/advisor/speaker: PharmaEssentia.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 15, 2023, through June 14, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-169-H01-P
Type of Activity: Application
Upon completing the posttest with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Assistant/Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 14, 2024. PAs should only claim commensurate with the extent of their participation.